Botulinum toxin in post-stroke patients: stiffness modifications and clinical implications.

J Neurol

Department of Neurology, Istituto Auxologico Italiano, IRCCS, Strada L. Cadorna 90, 28824, Piancavallo Oggebbio (VB), Italy.

Published: February 2004

Objective: To objectively quantify stiffness and clinical changes in the upper limb of poststroke patients following botulinum toxin (BT) injection.

Methods: Eighteen consecutive chronic post-stroke spastic patients were injected Botulinum toxin A in the forearm flexor spastic muscles. Spasticity was clinically evaluated with the Ashworth scale. Stiffness was measured with indices (passive stiffness index (ISI) and total stiffness index (TSI) obtained by mechanical wrist displacements induced by a torque motor,which could also provide the stretch reflex threshold speed (SRTS) from flexor muscles. Functional status was measured with the Barthel index and a specific hand ability scale, pain with a visual analogue scale (VAS). The ranges of voluntary wrist extension (EROM) and flexion (FROM) and wrist isometric extension and flexion (IE-IF) strength were also calculated.

Results: IE and EROM significantly increased, being respectively p < 0.01 and p < 0.05; also SRTS was augmented (p < 0.001),while TSI showed lower values (p < 0.001); the Ashworth score decreased at least one point. Hand function for selected tasks improved in 50% of patients, the Barthel index only in 4 (22 %), forearm pain was completely relieved in 3 patients (17 %).

Conclusions: BT can be considered a valid therapeutic tool in all spastic patients, because of immediate advantages: reduction of muscle hypertonia, pain relief, improvement in selected motor performances.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00415-004-0297-3DOI Listing

Publication Analysis

Top Keywords

botulinum toxin
12
spastic patients
8
patients
6
stiffness
5
toxin post-stroke
4
post-stroke patients
4
patients stiffness
4
stiffness modifications
4
modifications clinical
4
clinical implications
4

Similar Publications

: Giant cell tumor of bone (GCTB) is a locally aggressive tumor. It accounts for only 5% of all bony tumors. Early diagnosis, and follow-up for recurrence is often difficult due to a lack of biogenetic markers.

View Article and Find Full Text PDF

Introduction: To date, no investigations have been published regarding the concentration, dose, and technique for a mucosal spray application of botulinum toxin A (BTA) to alleviate hypersecretory symptoms of rhinitis in humans. It is a promising option for reducing common symptoms of seasonal allergic rhinitis (AR) and idiopathic non-AR. It is safer and less painful than intranasal injections, with high reported satisfaction in reducing clinical symptoms.

View Article and Find Full Text PDF

Limited Evidence of Functional Benefit After Upper Limb Botulinum Toxin Treatment in Children With Cerebral Palsy: Systematic Review and Meta-analysis.

Am J Phys Med Rehabil

February 2025

From the Centre for Translational Medicine, Semmelweis University, Budapest, Hungary (OZG, MV, MAE, LS, ZM, PH, TT); Department of Orthopaedics, Semmelweis University, Budapest, Hungary (OZG, MV, TT); Department of Anesthesiology and Intensive Therapy, Semmelweis University, Budapest, Hungary (ZM); Department of Anesthesiology and Intensive Therapy, Poznan University for Medical Sciences, Poznan, Poland (ZM); and Institute of Pancreatic Diseases, Semmelweis University, Budapest, Hungary (PH).

Objectives: This systematic review and meta-analysis of randomized controlled trials aimed to summarize the reported functional effects of upper limb botulinum toxin treatment in children with spastic cerebral palsy.

Design: Six databases were searched in October 2022. Two independent authors screened and extracted data on upper limb function, body function, life quality, muscle tone, spasticity, goals, pain, adverse events, and client satisfaction.

View Article and Find Full Text PDF

Recently, the Therapeutic Goods Administration (TGA) updated its guidance on cosmetic injectables advertising. The updates confirm that all direct or indirect advertising of cosmetic injectable products, including botulinum toxins or dermal fillers, is prohibited in Australia. While some commentators have lamented these updates, they present no changes to the law.

View Article and Find Full Text PDF

DaxibotulinumtoxinA Treatment for Laryngeal Respiratory Dystonia.

J Voice

January 2025

Department of Otolaryngology-Head and Neck Surgery, UCSF Voice and Swallowing Center, UCSF School of Medicine, San Francisco, CA. Electronic address:

Background: Laryngeal respiratory dystonia (LRD) is diagnosed based on clinical presentation, patient history, and physical examination. Key indicators include dyspnea, desynchronized breathing patterns, and laryngoscopic findings that reveal vocal fold adduction during inspiration. Treatment for LRD remains controversial and often yields limited effectiveness.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!